This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khan, A. A. Articles by Remington, J. S. Search for Related Content PubMed PubMed Citation Articles by Khan, A. A. Articles by Remington, J. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Aug 1996, 1855-1859, Vol 40, No. 8
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Trovafloxacin is active against Toxoplasma gondii

AA Khan, T Slifer, FG Araujo and JS Remington
Department of Immunology and Infectious Diseases. Palo Alto Medical Foundation, California 94301, USA.

Drugs currently used for treatment of toxoplasmosis in pregnant women, congenital infections, immunocompromised patients, and patients with the ocular disease are not always effective or may be dangerous to use; therefore, there is a need for more-effective and less-toxic drugs. Recently, we examined a group of fluoroquinolones for in vitro and in vivo activities against Toxoplasma gondii. Among those examined in vitro (ciprofloxacin, fleroxacin, ofloxacin, temafloxacin, and trovafloxacin), only trovafloxacin significantly inhibited intracellular replication of T. gondii without significant toxicity for host cells. In a murine model of acute toxoplasmosis, 100 or 200 mg of trovafloxacin per kg of body weight per day for 10 days protected 100% of infected mice against death. A dose of 50 mg/kg/day protected 90% of the mice, and a dose of 25 mg/kg/day effected prolongation of time to death. The other fluoroquinolones did not have such in vivo activities. These results indicate that trovafloxacin may be useful for treatment of toxoplasmosis in humans.

This article has been cited by other articles:

• Khan, A. A., Slifer, T. R., Araujo, F. G., Remington, J. S. (2001). Activity of Gatifloxacin Alone or in Combination with Pyrimethamine or Gamma Interferon against Toxoplasma gondii. Antimicrob. Agents Chemother. 45: 48-51 [Abstract] [Full Text]  
• Gozalbes, R., Brun-Pascaud, M., Garcia-Domenech, R., Galvez, J., Girard, P.-M., Doucet, J.-P., Derouin, F. (2000). Anti-Toxoplasma Activities of 24 Quinolones and Fluoroquinolones In Vitro: Prediction of Activity by Molecular Topology and Virtual Computational Techniques. Antimicrob. Agents Chemother. 44: 2771-2776 [Abstract] [Full Text]  
• Khan, A. A., Slifer, T. R., Araujo, F. G., Remington, J. S. (1999). Quinupristin-Dalfopristin Is Active against Toxoplasma gondii. Antimicrob. Agents Chemother. 43: 2043-2045 [Abstract] [Full Text]  
• Khan, A. A., Araujo, F. G., Brighty, K. E., Gootz, T. D., Remington, J. S. (1999). Anti-Toxoplasma gondii Activities and Structure-Activity Relationships of Novel Fluoroquinolones Related to Trovafloxacin. Antimicrob. Agents Chemother. 43: 1783-1787 [Abstract] [Full Text]  
• Khan, A. A., Nasr, M., Araujo, F. G. (1998). Two 2-Hydroxy-3-Alkyl-1,4-Naphthoquinones with In Vitro and In Vivo Activities against Toxoplasma gondii. Antimicrob. Agents Chemother. 42: 2284-2289 [Abstract] [Full Text]  
• Fischman, A. J., Babich, J. W., Bonab, A. A., Alpert, N. M., Vincent, J., Callahan, R. J., Correia, J. A., Rubin, R. H. (1998). Pharmacokinetics of [18F]Trovafloxacin in Healthy Human Subjects Studied with Positron Emission Tomography. Antimicrob. Agents Chemother. 42: 2048-2054 [Abstract] [Full Text]  
• Khan, A. A., Slifer, T. R., Remington, J. S. (1998). Effect of Trovafloxacin on Production of Cytokines by Human Monocytes. Antimicrob. Agents Chemother. 42: 1713-1717 [Abstract] [Full Text]